NBDF reaffirms its dedication to all in the bleeding disorders community, prioritizing health equity, diversity, and inclusion.

This activity is intended for learners to enhance their ability to recognize the key differences in gene therapies for hemophilia A compared with hemophilia B, and to leverage evolving data about gene therapies for hemophilia to better care for patients.

The FDA’s Fast Track designation is meant to facilitate the development and expedite the review of drugs that treat a broad range of serious conditions and address an unmet medical need.

The National Bleeding Disorders Foundation (NBDF) is pleased to announce the appointment of three new distinguished members to its Board of Directors, effective January 1, 2025.

A Distinguished Leader in the Bleeding Disorders Community

The resources in this edition includes articles, videos, and additional background information relevant to the ever-evolving technologies that are driving exciting advances in bleeding disorders treatment and care.

ITP is a rare autoimmune disorder that causes a significant reduction in platelets, which are necessary for clotting.

VGA039 is a subcutaneously-delivered monoclonal antibody therapy designed to target Protein S as a means of restoring proper blood clotting in people with all types of von Willebrand disease.

Female hemophilia carriers often go undiagnosed. Learn about the importance of identifying and supporting these individuals to ensure equitable access to care.